Synergistic action of alkylating agents and methylxanthine derivatives in the treatment of chronic lymphocytic leukemia.
Binet
J L
JL
Mentz
F
F
Leblond
V
V
Merle-Beral
H
H
D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002699:Chlorambucil / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D004357:Drug Synergism; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy*; D010431:Pentoxifylline / Q000008:administration & dosage; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use*; D013806:Theophylline / Q000008:administration & dosage; D014970:Xanthines / Q000008:administration & dosage
D018906:Antineoplastic Agents, Alkylating; D010726:Phosphodiesterase Inhibitors; D014970:Xanthines; D002699:Chlorambucil; C008514:methylxanthine; D003520:Cyclophosphamide; D013806:Theophylline; D010431:Pentoxifylline